Perspectives on Cancer Genome Profiling

PGDx BLOG

PGDx Takes on ASCO

Every year, 40,000 oncology professionals gather in Chicago for ASCO (American Society of Clinical Oncology), the largest cancer conference in the world. Presenters at this meeting reveal new findings on promising therapies, introduce intriguing theories on anything from cancer biology to clinical practice, and inevitably spark controversial discussions from around the field…

MSI 2.0

On May 23, the FDA announced it has granted accelerated approval of Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for use as a pan-cancer therapeutic in solid tumors with detectable levels of the microsatellite instability-high (MSI-H) biomarker. This is the first time the FDA has approved a cancer treatment targeting a specific genetic feature…

MSI Analysis Makes PlasmaSELECT 64 Even More Powerful.

PGDx is excited to announce we’ve expanded PlasmaSELECT 64 to add microsatellite instability analyses. Called PlasmaSELECT 64 + MSI, it is now the only pan-cancer assay for tumor profiling that can also evaluate MSI status in plasma.PlasmaSELECT 64 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple cancer…

Genomic Predictors of Immunotherapy Response

One of the most cutting-edge pan-cancer biomarkers for response to cancer therapeutics is microsatellite instability (MSI). Resulting from deficient mismatch-repair (MMR), MSI is a clinically relevant condition characterized by the progressive shortening of mononucleotide genomic tracts. With recent advances in precision medicine, our ability to detect MMR deficiency in patients has taken…

Tumor Evolution: A Resistance Mechanism To Checkpoint Blockade Inhibitors

Tumor cells are readily targeted and destroyed by the body’s army of cytotoxic T cells.  Normally, checkpoint blockade proteins on the outer membrane of T cells, such as programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), distinguish between “self” and “non-self” cells. Checkpoint blockade inhibitors (CBIs), such as anti-PD-L1 (pembrolizumab)…

Liquid Biopsy: Addressing the need, when tissue is an issue

For oncologists, molecular testing of tissue biopsies currently remains the gold standard for best understanding a patient’s disease and recommending treatment modalities. Unfortunately, there are multiple scenarios where tissue is not available or of sufficient quantity and quality for testing. For example, 10-25% of NSCLC patients may have an insufficient tissue for…

The Fault in Our DNA

“What am I at war with? My cancer. And what is my cancer? My cancer is me.  The tumors are made of me.  They’re made of me as surely as my brain and my heart are made of me.  It is a civil war… with a predetermined winner.”- John GreenEach one of…